- Patent Title: Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
-
Application No.: US16050227Application Date: 2018-07-31
-
Publication No.: US10392368B2Publication Date: 2019-08-27
- Inventor: Erik Fenster , Tom M. Lam , Mandy Loo , Robert Murray McKinnell , Anthony Francesco Palermo , Diana Jin Wang , Breena Fraga , Jerry Nzerem , Marta Dabros , Venkat R. Thalladi , Miroslav Rapta
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agent Jeffrey A. Hagenah; Florence Jovic
- Main IPC: A61P1/00
- IPC: A61P1/00 ; A61P17/00 ; A61P29/00 ; A61P35/00 ; C07D401/12 ; C07D403/12 ; C07D413/12 ; C07D471/04 ; C07D487/04

Abstract:
The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
Public/Granted literature
- US20190040043A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS Public/Granted day:2019-02-07
Information query